

TOSHKENT TIBBIYOT AKADEMIYASI
«YOSH OLIMLAR TIBBIYOT JURNALI»

TASHKENT MEDICAL ACADEMY
«MEDICAL JOURNAL OF YOUNG SCIENTISTS»

ТАШКЕНТСКАЯ МЕДИЦИНСКАЯ АКАДЕМИЯ
«МЕДИЦИНСКИЙ ЖУРНАЛ МОЛОДЫХ УЧЕНЫХ»

IXTISOSLASHUVI: «TIBBIYOT SOHASI»

ISSN 2181-3485

Mazkur hujjat Vazirlar Mahkamasining 2017 yil 15 sentabrdagi 728-son qarori bilan tasdiqlangan O'zbekiston Respublikasi Yagona interaktiv davlat xizmatlari portali to'g'risidagi nizomga muvofiq shakllantirilgan elektron hujjatning nusxasi hisoblanadi.

№ 2 (07), 2022



Jurnaldagi nashrlar O'zbekistonda va xorijda ilmiy darajalar uchun dissertatsiyalar himoya qilinganda chop etilgan ishlar deb hisoblanadi.

Ilgari hech qayerda chop etilmagan va boshqa nashrlarda chop etish uchun taqdim etilmagan maqolalar nashrga qabul qilinadi. Tahririyatga kelgan maqolalar ko'rib chiqiladi. Nashr mualliflari maqolalarda keltirilgan ma'lumotlarning to'g'riligi uchun javobgardirlar. Materiallardan foydalanganda jurnalga va maqola mualliflariga havola bo'lishi shart.

Materiallar mualliflik nashrida chop etiladi.

Публикации в журнале учитываются как опубликованные работы при защите диссертаций на соискание ученых степеней Узбекистана и зарубежья.

К публикации принимаются статьи, ранее нигде не опубликованные и не представленные к печати в других изданиях. Статьи, поступившие в редакцию, рецензируются. За достоверность сведений, изложенных в статьях, ответственность несут авторы публикаций. При использовании материалов ссылка на журнал и авторов статей обязательна.

Материалы публикуются в авторской редакции.

ГЛАВНЫЙ РЕДАКТОР

Шадманов Алишер Каюмович

ЗАМЕСТИТЕЛЬ ГЛАВНОГО РЕДАКТОРА

Шайхова Гули Исламовна

ОТВЕТСТВЕННЫЙ СЕКРЕТАРЬ

Алимухамедов Дилшод Шавкатович

ЧЛЕНЫ РЕДАКЦИИ:

т.ф.д., доцент Азизова Ф.Л.
профессор Камилов Х.П.
т.ф.д. Набиева Д.А.
профессор Тешаев О.Р.
профессор Хасанов У.С.

профессор Азизова Ф.Х.
профессор Каримжонов И.А.
профессор Наджмутдинова Д.К.
профессор Хайдаров Н.К.
т.ф.д. Худойкулова Г.К.

профессор Аллаева М.Ж.
профессор Каримова М.Х.
т.ф.д. Нуриллаева Н.М.
профессор Хакимов М.Ш.
профессор Эрматов Н.Ж.

РЕДАКЦИОННАЯ КОЛЛЕГИЯ

Аглиулин Д.Р.	к.м.н. (Россия)	Саломова Ф.И.	д.м.н. (Тошкент)
Ачилов Д.Д.	PhD (Термез)	Санаева М.Ж.	д.м.н. (Тошкент)
Ганиев А.А.	д.м.н. (Тошкент)	Сидиков А.А.	д.м.н. (Фарғона)
Искандарова Г.Т.	профессор (Тошкент)	Собиров У.Ю.	профессор (Тошкент)
Матназарова Г.С.	д.м.н. (Тошкент)	Тажиева З.Б.	PhD (Ургенч)
Мирзоева М.Р.	д.м.н. (Бухоро)	Ташкенбаева У.А.	д.м.н. (Тошкент)
Муртазаев С.С.	д.м.н. (Тошкент)	Тусунов Ж.Х.	PhD (Тошкент)
Нарзикулова К.И.	д.м.н. (Тошкент)	Хасанова Д.А.	д.м.н. (Бухоро)
Носиров М.М.	PhD (Андижон)	Хасанова М.А.	к.м.н. (Тошкент)
Орипов Ф.С.	д.м.н. (Самарқанд)	Хван О.И.	д.м.н. (Тошкент)
Рахимов Б.Б.	д.м.н. (Жанубий Корея)	Холматова Б.Т.	профессор (Тошкент)
Рустамова М.Т.	профессор (Тошкент)	Чон Хи Ким	PhD (Жанубий Корея)

Адрес редакции:

Ташкентская медицинская академия 100109, г.
Ташкент, Узбекистан, Алмазарский район, ул. Фараби 2,
тел.: +99878-150-7825, факс: +998 78 1507828,
электронная почта: mjys.tma@gmail.com

**Toshkent tibbiyot
akademiyasi
«Yosh olimlar tibbiyot
jurnali»**



**Tashkent Medical
Academy
«Medical Journal of
Young Scientists»**

• № 2 (07) 2022 •

ОГЛАВЛЕНИЕ

ОБЗОРЫ

Karlibaev A., Dilsora M., Tillyashaykhov M.N. Trimodal therapy as an organ-preserving method of treatment for bladder cancer	8
Jamolov A.Sh., Ahmedova N.A. Psychological aspects of commitment treatment of patients with rheumatoid arthritis	18
Salimova M.R., Narmuratova F.Q. When will the COVID-19 pandemic officially end?.....	19
Акназарова Д.Б. Биологически активные добавки к пище	21
Dauletnazarov N.K., Matnazarova G.S., Madreimov A.M., Bryansteva E.V. Specific prevention and diagnosis of tuberculosis	28
Рахимова Ш.Э., Талипов Р.Р., Якубова М.М. Кишечная микробиота - орган поддерживающий гомеостаз	33

НОВЫЕ ПЕДАГОГИЧЕСКИЕ ТЕХНОЛОГИИ

Xalmuhamedov, B.T. Bo'lajak oilaviy shifokorlarning kasbiy motivatsiyasini oshirishda teletibbiyot texnologiyalarining ahamiyati	39
Хамидов Х.А. Актуальные проблемы обучения латинскому языку в медицинском ВУЗе ...	45

КЛИНИЧЕСКАЯ МЕДИЦИНА

Bobojonov O.H., Sattarov O.T. Noparazitar taloq kistalarini jarrohlik yo'li bilan davolash.....	49
Yuldosheva S.U. Hemostatic changes in patients with autoimmune thyroiditis	57
Salayeva N.M., Raxmonova N.X. Qizlarda vulvovaginit uchrash chastotasi, xavf omillari va sinexiya bilan asoratlanish profilaktikasi	59
Абдужабарова З.М., Худойберганов М.Р. Динамика клинических признаков у детей с целиакией на фоне различных методов лечения	63
Абдужабарова З.М., Камалов З.С., Шодиева М.С., Худайберганов М.Р. Генетические маркеры helicobacter pylori ассоциированной язвенной болезни двенадцати перстной кишки	65

Ахадов М.М., Халиков С.П. Хирургическое лечение протяженных и двухуровневых рубцовых стриктур трахеи	68
Babadjanova F.R. Optimization of diagnosis, prognosis and treatment of cardiac disorders in children with congenital heart defects, in children living in the khorezm region.....	75
Бабаджанова Ф.Р., Довлетова Г.О. Перинатальные исходы у женщин и заболеваемость детей, рожденных во время пандемии covid-19 в хорезмской области.....	79
Во‘riyeva Sh.Sh., Iskandarova D.E. Insult diagnostikasida mskt taxlilining natijalari va ahamiyati.....	81
Жураев С.Б., Асраров У.А. Оптимизация тактики хирургического лечения повреждений артерий конечностей при сочетанных травмах.....	82
Аваков В.Е., Ибрагимов Н.К., Кенжаев Л.Т, Журакулов А.К., Наубетова С.Д. Влияние препарата каллидиногеназы на гемостаз, когнитивные функции и показатели гемодинамики при изолированной закрытой черепно-мозговой травмой.....	87
Курбанбаев Р.И., Асраров У.А. Тактика хирургического лечения больных с тромбозами артерий нижних конечностей	95
Тажиева З.Б. Особенности развития оксалатной нефропатии у детей и взаимосвязь с патологией пищеварительного тракта	100
Холмаматов Х.Т., Халиков С.П. Рубцовый стеноз трахеи: эндоскопическая диагностика и лечение.....	104
Худайбергандов М.Р. Роль микроэлементов и иммунной системы при госпитальной инфекции у детей раннего возраста	113

ГИГИЕНА, САНИТАРИЯ И ЭПИДЕМИОЛОГИЯ

Камилова А.Ш. Проблема питания при психоэмоциональных состояниях, приводящих к ожирению	115
Камилова Р.Т., Носирова А.Р., Исакова Л.И., Камиллов Ж.А. Болалар жисмоний ривожланишининг овқатланишни ташкил этилганлигига боғлиқлиги.....	122
Абдуллаева Д.Г. Овқат аллергиясида яширин алергенларни аниқлаш бўйича амалий тавсиялар.....	129
Абдуллаева Д.Г., Ҳақбердиев Х.Р. Озиқ-овқат маҳсулотлари ва замбуруғларга сезувчанлик ва унинг профилактикаси.....	136
Исакова Л.И., Атаниязова Р.А., Камилова Р.Т., Усманова М.И., Кусбергенова Х. Анализ уровня знаний в области влияния санитарии и гигиены на состояние здоровья и благополучие населения республики.....	142
Камилова Р.Т., Тиллаева Шт.О., Тиллаева Шд.О. Значение рационального питания для здоровья юных спортсменов	149
Тураев Ф.Ш. Новые макаронные изделия с обогащением белкового изолята	153

ЭКСПЕРИМЕНТАЛЬНАЯ БИОЛОГИЯ И МЕДИЦИНА

**Ишанджанова С.Х., Азизова Ф.Х., Отажанова А.Н., Махмудова Ш.И.,
Миртолипова М.А.** Показатели физического развития и морфологические особенности
стенки тонкой кишки крысят, родившихся в условиях гипотиреоза у матери..... 160

Худайбергганов М.Р., Атажанов Х.П. Анализ статуса железа у беременных как основа
прогноза риска развития железодефицитных состояний у детей 166

ДОКАЗАТЕЛЬНАЯ МЕДИЦИНА

Muhammad Arsalan Ali Sajid, Ismoilova Z.A. Multi-system inflammatory syndrome
in children (MSI-C), is a rare but a serious condition. (a prospective study in Khorezm region)... 167

УДК: 616-002.5-07-084

SPECIFIC PREVENTION AND DIAGNOSIS OF TUBERCULOSIS

Dauletnazarov N.K., master

Matnazarova G.S., DSc., head of the department

Madreimov A.M., DSc, professor

Bryansteva E.V., CMSc., teacher

Department of Epidemiology of the Tashkent medical academy

Annotation: *The paper presents data on the state of tuberculosis in developed, developing countries and in the Republic of Uzbekistan; on the methods of prevention and diagnosis of tuberculosis used in the world health community to date; on WHO reports on tuberculosis; on the implementation of the WHO tuberculosis eradication strategy; data on the dynamics of the prevalence of tuberculosis in various countries.*

Keywords: *tuberculosis, tuberculosis prevention, tuberculosis treatment, tuberculosis with broad drug resistance (XDR-TB), World Health Organization (WHO).*

SIL KASALLIGINING MAXSUS PROFILAKTIKASI VA DIAGNOSTIKASI

Annotatsiya: *Ish quyidagilarni o'z ichiga oladi: rivojlangan, rivojlanayotgan mamlakatlarda va O'zbekiston Respublikasida sil kasalligining holati; jahon sog'liqni saqlash jamiyatida qo'llanilayotgan sil kasalligini oldini olish va tashxislash usullari; JSST sil kasalligi bo'yicha hisobotlari; JSST sil kasalligini bartaraf etish strategiyasini amalga oshirish to'g'risida; turli mamlakatlarda sil kasalligining tarqalishi dinamikasi to'g'risidagi ma'lumotlar.*

Kalit so'zlar: *sil kasalligi, sil kasalligini oldini olish, sil kasalligini davolash, keng dori-darmonga chidamli sil(KDCH-TB), Jahon sog'liqni saqlash tashkiloti (JSST).*

СПЕЦИФИЧЕСКАЯ ПРОФИЛАКТИКА И ДИАГНОСТИКА ТУБЕРКУЛЁЗА

Аннотация: *В работе приведены данные: о состоянии по туберкулёзу в развитых, развивающихся странах и в Республике Узбекистан; о методах профилактики и диагностики туберкулёза, применяемые в мировом сообществе здравоохранения к настоящему времени; об отчётах ВОЗ по туберкулёзу; о реализации стратегии ликвидации туберкулёза ВОЗ; данные о динамике распространённости туберкулёза в различных странах.*

Ключевые слова: *туберкулёз, профилактика туберкулёза, лечение туберкулёза, туберкулёз с широкой лекарственной устойчивостью (ШЛУ-ТБ), Всемирная организации здравоохранения (ВОЗ).*

Relevance.

In recent years, tuberculosis has been one of the big problems of modern medicine. The World Health Organization (WHO) has

recognized tuberculosis as one of the five global problems of mankind. WHO estimates that 10 million people worldwide fell ill with tuberculosis in 2019, including 5.6 million

men, 3.2 million women and 1.2 million children. Tuberculosis is common in all countries and age groups. Tuberculosis is curable and preventable.

It can be difficult to diagnose and treat tuberculosis in children and adolescents, and the disease at this age often remains unrecognized by health workers.

In 2019, the 30 countries with a heavy burden of tuberculosis accounted for 87% of new cases of tuberculosis. Two-thirds of the cases occurred in eight countries, among which India ranked first, followed by Indonesia, China, the Philippines, Pakistan, Nigeria, Bangladesh and South Africa.

Purpose of research

To study the methods of specific prevention and diagnosis of tuberculosis in developed and developing countries and compare them with the methods in the Republic of Uzbekistan.

Study of articles by international authors in the field of specific prevention and diagnosis of tuberculosis.

Materials and methods

The research materials are the reporting data of the Sanitary and Epidemiological Welfare and Public Health Service of the Republic of Karakalpakstan, articles by international authors on the topic "Diagnosis and specific prevention of tuberculosis", articles on the official WHO website.

The research method is a meta-analysis based on the above data.

Results and discussions

With the development of science, the BCG vaccine was developed. In Uzbekistan, this vaccine is used only once on the 2-5 birthday of a child, and is administered directly in Prenatal centers. It has been proven that this vaccine protects only from tuberculous meningitis, rather than from tuberculosis itself. In an article called "The impact of a change in infant BCG vaccination policy on adolescent TB incident rates: A South African population-level

cohort study" (The impact of a change in BCG infant vaccination policy on the incidence of tuberculosis among adolescents: a cohort study at the population level of South Africa), it was concluded that a change in policy regarding vaccination of children with BCG was associated with a moderate decrease in the incidence of tuberculosis among HIV-negative adolescents aged 10 to 17 years. However, the incidence of TB increased rapidly with age in both cohorts of adolescents and remained high despite BCG vaccination at birth [1].

Scientists from the People's Republic of China have proved that the introduction of BCG vaccine significantly reduces the risk of asthma by 23%, which indicates its protective effectiveness against the development of asthma among vaccinated children. However, early administration of the BCG vaccine did not significantly reduce the risk of eczema and rhinitis (BCG vaccination in early childhood and the risk of atopic diseases: a systematic review and meta-analysis) [2].

BCG vaccine is also used in the field of oncology in the treatment of various tumor diseases. An example of this is the following article by Bacillus Calmette-Guérin (BCG) and alternatives: Drug treatment of high-risk non-muscle invasive bladder cancer (Drug treatment of high-risk non-muscle invasive bladder cancer [4].

In any infectious diseases, its diagnosis is important. At the present stage, there are several ways to diagnose tuberculosis in children: tuberculin test (Mantoux test), Diaskin test, Quantiferon test. The very first and widely used diagnostic method is the Mantoux test. Advantages of this method: availability and cheapness of the drug; the disadvantages include: the need for special care of the injection site, allergic reactions to tuberculin often occur, children scratch the injection site, after which a false positive reaction may appear, including false negative results are also not excluded. But currently, this test has been can-

celed in Uzbekistan, the effectiveness of the diagnosis of tuberculosis, which is only 0.03% of cases.

To completely exclude false positive reactions, you can resort to a Diaskin test. Often in practice there are cases when the parents of a child refuse a tuberculin test, considering it toxic. In this regard, the Diaskin test is much "Cleaner" than the Mantoux test, since it does not have mycobacterium components, and contains proteins identical to mycobacterium proteins. The disadvantages of the Diaskin test include: the high cost of the test, it is not able to detect hidden and latent forms of the disease, it can also be false negative. According to the latter criterion, the Quantiferon test is one of the most reliable, since it can make an early diagnosis of tuberculosis. The first methods of diagnosing tuberculosis listed above have one common drawback: you need to inject the drug into the body and wait for the result, which can be influenced by many factors that will directly affect the result. In this regard, the Quantiferon test is considered independent of the state of the body at that time, and blood from a vein is needed for diagnosis. Also, the most significant advantages of the Quantiferon test are: the ability to carry out diagnostics in children's institutions during quarantine, in HIV-infected people, with contraindications to many drugs. A significant disadvantage of this diagnostic method is the inability to distinguish cow tuberculosis from human tuberculosis, and it also does not distinguish between ordinary infection and disease.

With these data, we can say that there is no ideal method for diagnosing tuberculosis at the moment. It is necessary to diagnose this disease in stages and systematically. The above methods make it possible to identify children who need a phthisiologist's consultation, preventive treatment or full-fledged anti-tuberculosis care.

In the diagnosis of tuberculosis in Uzbekistan, the main method is mass fluorography.

Guidelines for the diagnosis and treatment of tuberculosis developed by the American Thoracic Society, the American Society of Infectious Diseases Specialists and the Centers for Disease Control and Prevention (CDC) have been updated in the United States. They recommend using the new immunological diagnostic method IGRA (Interferon Gamma Release Assays) instead of a standard skin test with a tuberculin solution (Mantoux test). The IGRA method is based on measuring the immune response of T-lymphocytes to highly specific mycobacterial antigens ESAT-6 and CFP-10, expressed by the production of gamma interferon in a 24-hour whole blood culture. Its use increases the specificity of the results obtained, especially in patients who have received preliminary BCG vaccination. In addition, one visit to a medical institution is enough for this examination. After the diagnosis of latent tuberculosis, preventive treatment with isoniazid is recommended [3].

The European Tuberculosis Laboratory Initiative (ELI), together with the secretariat at the WHO Regional Office for Europe, has developed a technical document to meet the needs for more timely and accurate detection of tuberculosis (TB), including multidrug-resistant tuberculosis (MDR-TB) in the WHO European Region by scaling up the appropriate use of rapid molecular methods diagnostics recommended by WHO [5].

Scientists believe that in conditions of high risk of transmission of TB and/or MDR-TB (for example, penitentiary institutions of the former Soviet Union), annual sputum screening by PCR (GeneXpert MTB/RIF) has demonstrated greater cost-effectiveness for reducing TB and MDR-TB compared to traditional methods.

In the Russian Federation, molecular diagnostics of tuberculosis is widely used, which

include IS6110-RFLP typing, VNTR typing, spoligotyping and sequencing. The first three can be attributed to obsolete, and sequencing — to modern methods. With the help of genome-wide sequencing, both neutral markers and mutations leading to drug resistance can be detected. Molecular genetic methods in phthisiology are used to solve the following tasks: detection of MBTC, detection of non-tuberculosis mycobacteria (NTMB), identification of mycobacteria to the species and determination of drug sensitivity (HP). Kits for detecting MBTC using real-time PCR are widely available on the market [6].

Treatment recommendations that have been updated in new WHO protocols:

- For the treatment of patients with drug-sensitive pulmonary TB, the use of treatment regimens containing fluoroquinolones lasting 4 months is not recommended. It is recommended to use rifampicin-based regimens lasting 6 months (2 months – isoniazid + rifampicin + pyrazinamide + ethambutol and 4 months - isoniazid + rifampicin).

- All patients with HPV TB are not recommended to take medications three times a week in both phases of treatment, intensive and continuation phase, but daily medication is recommended.

- Patients who need repeated TB treatment should not receive a second-category treatment regimen (standard TB treatment regimen + streptomycin). Such patients need to be tested for drug sensitivity in order to choose the appropriate treatment.

- In the treatment of drug-sensitive TB, the use of combination drugs with a fixed dosage, rather than monocomponents, is recommended.

- All patients with TB and HIV should start ARV therapy regardless of the amount of DM4. TB treatment should be started first, and then ARV drugs should be started as soon as possible during the first 8 weeks of treatment. HIV-positive patients with CD4 of less than 50

cells should start ARV therapy within the first two weeks from the start of TB treatment [7].

In Uzbekistan, until 2019, the DOTS (Directly Observed Treatment, Short-course) strategy functioned — this is "treatment under direct control with a short course"). Political support of this strategy by the authorities at all levels and the government's commitment to ensure the implementation of measures to combat tuberculosis:

- detection of tuberculosis cases using bacterioscopic examination of sputum smears in patients with symptoms of the disease (according to the treatment);

- Conducting treatment according to standardized regimens under direct supervision during the entire course of chemotherapy;

- Regular, uninterrupted supply of all major anti-tuberculosis drugs;

- A standardized system of registration and reporting, which allows assessing the results of each patient and the effectiveness of the tuberculosis control program as a whole.

In some post-Soviet countries (Russia, Ukraine) a number of experts consider the DOTS strategy to be insufficiently effective and significantly inferior to the comprehensive anti-tuberculosis strategy developed and implemented in the USSR, based on a developed network of anti-tuberculosis dispensaries. (V. M. Melnik, "Tuberculosis and DOTS") According to WHO statistics, a total of 1.4 million people died from tuberculosis in 2019 (including 208,000 people with HIV infection). Worldwide, tuberculosis is one of the 10 leading causes of death and the main cause of death due to any one causative agent of infection (ahead of HIV/AIDS). Tuberculosis is common in all countries and age groups [9].

Drug-resistant tuberculosis continues to pose a serious threat to public health. In 2019, almost half a million people worldwide fell ill with Rifampicin-resistant tuberculosis (RU-TB), 8 of which 78% contracted multidrug-resistant tuberculosis (MDR-TB)9. Three coun-

tries accounted for the largest share of the global burden: India (27%), China (14%) and the Russian Federation (8%). The proportion of MDR/RU-TB cases worldwide was 3.3% among new cases and 17.7% among previously treated cases of tuberculosis and was the highest (over 50% among previously treated cases) in the countries of the former Soviet Union.

The main measure in the field of health care, which reduces the risk of tuberculosis infection becoming active, is preventive treatment. In accordance with the WHO guidelines, preventive treatment of tuberculosis is recommended for the following groups: people living with HIV; people in contact at the household level with patients with bacteriologically confirmed pulmonary tuberculosis; and people at risk by clinical status (for example, dialysis patients). In 2019, 4.1 million people worldwide received preventive treatment for tuberculosis, whereas in 2018 there were only 2.2 million of them.

Drug-resistant forms of tuberculosis are also important, which need full-fledged treatment not only to prevent the further spread of the disease, but also to prevent the conversion of drug-sensitive forms into XDR or MDR tuberculosis. Due to the toxic manifestations of tuberculosis drugs, patients often refuse to use them. In order to mitigate the situation, active psychological educational work is being carried out with tuberculosis patients. In 2019 77% of the difference between the number of patients referred for treatment and the estimated number of new MDR/RU-TB cases in the world occurred in 10 countries, which largely determine how successful the process of closing this gap will be. Forty-one percent of this difference is only in China and India. According to the latest data on the results of patient treatment, the success rate of MDR/RU-TB treatment in the world was 57%. Examples of countries with a heavy burden of MDR-TB and relatively high rates of success-

ful MDR/RU-TB treatment (over 75%) are Ethiopia, Kazakhstan and Myanmar.[8]

According to the Implementation of the WHO tuberculosis eradication strategy, countries with a high burden of tuberculosis will have to ensure by 2025: the development and implementation of a national tuberculosis research plan; the creation of stable funding mechanisms for national tuberculosis research; the creation of significant scientific potential; the formation of a strong and autonomous community for tuberculosis research [10]

Tuberculosis of children is important. It can be difficult to diagnose and treat tuberculosis in children and adolescents, and the disease at this age often remains unrecognized by health workers.

According to official statistics, the incidence of tuberculosis in the Republic of Karakalpakstan in 2011, approximately 7% of all primary registered cases of tuberculosis were tuberculosis in children under 14 years of age. The intensive indicator among all those who were initially infected in 2011 was 103.6 per 100 thousand of the population, compared with 2020, in which this indicator was 58.1 per 100 thousand of the population. Over 10 years, the incidence has decreased by 36% overall, by 41% in children. These figures undoubtedly speak about the effectiveness of the tuberculosis control strategy in the Republic of Uzbekistan.

Conclusions

According to all the above data, we can say that tuberculosis is still considered one of the main unresolved problems not only at the state level, but also at the international level. The most leading factor in the development of the incidence of tuberculosis is the social factor. This can be answered by the widespread prevalence of tuberculosis in developing countries. Despite the development of many methods of diagnosing tuberculosis, diagnosis is considered to be one of the leading problems, since no method is fully accurate and practical.

In addition, we can say that methods of treating tuberculosis have already been developed, but due to the refusal of patients from a full course of treatment, forms with broad and multidrug resistance are developing that are almost untreatable. Thus, tuberculosis remains an urgent problem of world health.

REFERENCES

1. Fack C, Wood R, Hatherill M, Cobelens F, Hermans S - The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study - <https://web.p.ebscohost.com/ehost/detail/detail?vid=9&sid=aa7e57fa-54d0-44c5-b06e-b81ad9f5d83c%40redis&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#AN=34872798&db=mnh>
2. Leucht K, Foller S, Grimm MO - BCG Vaccination in Early Childhood and Risk of Atopic Disease: A Systematic Review and Meta-Analysis <https://web.p.ebscohost.com/ehost/detail/detail?vid=25&sid=aa7e57fa-54d0-44c5-b06e-b81ad9f5d83c%40redis&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#AN=34709440&db=mnh>
3. Zhao K, Miles P, Jiang X - BCG Vaccination in Early Childhood and Risk of Atopic Disease: A Systematic Review and Meta-Analysis. <https://web.p.ebscohost.com/ehost/detail/detail?vid=17&sid=aa7e57fa-54d0-44c5-b06e-b81ad9f5d83c%40redis&bdata=JnNpdGU9ZWhvc3QtbGl2ZQ%3d%3d#AN=34868440&db=mnh>
4. <https://pharm.reviews/novosti/zaru-bezhnye-novosti/item/1670-v-ssha-obnovleno-rukovodstvo-po-dagnostike-i-lecheniyu-tuberkuleza>
5. <https://pcr.news/novosti/molekulyarnaya-dagnostika-tuberkuleza-v-rossii/>
6. Алгоритм лабораторной диагностики и мониторинга лечения туберкулеза легких и туберкулеза с лекарственной устойчивостью на основе применения современных быстрых молекулярных методов - https://www.euro.who.int/__data/assets/pdf_file/0004/336118/ELI-TB-Laboratory_diag_algorithm_RUS.pdf.
7. Глобальный доклад ВОЗ по борьбе с туберкулезом. Резюме 2020г
8. Информационная бюллетень ВОЗ по туберкулезу - <https://www.who.int/ru/news-room/fact-sheets/detail/tuberculosis>
9. Реализация стратегии ликвидации туберкулеза: Основные положения. ВОЗ.
10. Рекомендации ВОЗ по лечению туберкулеза - <https://www.itpcru.org/2017/05/01/obnovleny-rekomendatsii-voz-po-lecheniyu-tuberkuleza/>